Evolva (Switzerland) a clinical-stage synthetic biology small molecule company focused on proteinuri kidney and cardiovascular disease, closed a $15.2M Series B financing bringing the total round up to $42.3M. Participants include Wellington Partners, Aravis Venture Associates, Auriga Partners and Vinci Capital.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Xigen (Switzerland) a clinical-stage biopharma company focused on Jun Kinase inhibitor for stroke, inflammation and hearing loss, closed a $20M Series B financing. Participants have included Tilocor Life Sciences, VI Partners and DEFI Gestion.

Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Evolva (Switzerland) a clinical-stage synthetic biology small molecule company focused on proteinuri kidney and cardiovascular disease, closed a $27,5M Series B financing. Participants include Wellington Partners Venture Capital, Aravis Venture Associates, Auriga Partners and Vinci Capital.

Celladon (La Jolla, CA) a clinical-stage company focused on gene therapy for congestive heart failure, closed a $21.8M Series C financing. Participants include Enterprise Partners Venture Capital, Venrock and Johnson & Johnson Dev Corp.

Arginetix (Baltimore, MD) a preclinical-stage pharmaceutical company focused on the small molecule inhibition of arginase for pulmonary arterial hypertension, closed a $4.6M Series B financing. Participants include Quaker BioVentures, MedImmune Ventures, Red Abbey Venture Partners, Maryland Health Care Product Development Corp. and Acidophil.

miRagen Therapeutics (Boulder, CO) a preclinical-stage biopharmaceutical company focused on the development of miRNA therapeutics for cardiovascular and muscle diseases, closed a $4 Series B, bringing the total round financing to $12M. Participants include Boulder Ventures, Amgen Ventures, Broadview Ventures, The Peierls Foundation and Atlas Venture.

Surface Logix (Brighton, MA) a clinical-stage small molecule company focused on metabolic and cardiovascular disease, closed a $15M Series E financing. Participants include ARCH Venture Partners, HBM BioVentures, Healthcare Focus, Intel Capital, Saudi Venture Development Co., Unilever Technology Ventures and Venrock.

Ardian (Palo Alto, CA) a clinical-stage medical device company focused on catheter-based treatment for hypertension, chronic kidney disease and heart failure, closed a $47M Series C financing. Participants include Medtronic, Emergent Medical Partners, Advanced Technology Ventures, Morgenthaler Ventures and Split Rock Partners.

Relypsa (Santa Clara, CA) a clinical-stage developer of a therapeutic for hyperkalemia in congestive heart failure patients closed a $10M Series A financing, the final tranche of the $43M round. Participants include 5AM Ventures, New Leaf Partners, Sprout Group, Delphi Ventures, CMEA Ventures and Mediphase Venture Partners.

Crux Biomedical (Menlo Park, CA) a clinical-stage is developing an implantable vascular device that offers potential improvement over existing inferior vena cava filter filters for treating and preventing pulmonary embolisms, closed an $8M Series B financing. Participants include Alloy Ventures and 1963 inventor of the balloon embolectomy catheter Thomas Fogarty.